Ana Baramidze, MD, head of the Department of Clinical Researches at the Todua Clinic in Tbilisi, Georgia, explained how clinicians can decide how to cemiplimab, which has a low discontinuation rate.
Ana Baramidze, MD
Advertisement
head of the Department of Clinical Researches at Todua Clinic in Tbilisi, Georgia
Articles by Ana Baramidze, MD
Cemiplimab demonstrated a 56% overall survival rate, making it a potential option for physicians to use for treating non–small cell lung cancer (NSCLC).
EMPOWER-Lung 3 Trial Results Find Cemiplimab Plus Chemotherapy Effective in NSCLC: Ana Baramidze, MD
Cemiplimab plus chemotherapy was found to be consistently effective in treating non-small cell lung cancer (NSCLC) and held up in the EMPOWER-Lung 3 trial.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
NYC Marathon Death Puts Rhabdomyolysis Risk Factors in Focus
2
Acoramidis Linked to Fewer Hospitalizations Than Tafamidis in ATTR-CM
3
Real-World Evidence, Rare Liver Disease Data Headline Kidney Week 2026
4
EEOC Reportedly Plans to Narrow Pregnancy Accommodation Rules
5